Latest Articles

This article explores how biopharmaceutical organizations seeking to remain competitive must adopt innovations, like cell-free long DNA synthesis, to unleash the potential of synthetic biology and accelerate therapeutic development across all facets of genetic medicine.

Dr. Darrell Green's best friend, Ben, developed bone cancer and passed away just before his 14th birthday. This profile article explores how this experience stayed with Green, and has propelled his work towards a new treatment for bone cancer.

A diverse array of biological medicines are now used to prevent and treat a wide range of illnesses. This article will discuss the development of cell lines in biopharma and will touch on key considerations, such as future manufacturability.

In this opinion piece, Neil Ward explores how advances in sequencing could help to provide new insights for rare disease patients.

Insight into the history of human–pathogen interactions, how different societies responded to disease and the origin of pathogens supports our understanding of human health and evolution. We explore what we're still learning about ancient pathogens and diseases.

A microbiome analysis study highlights that pandemic-related lifestyle changes may be responsible for alterations seen in the microbial profile of the small intestine before versus during the COVID-19 pandemic.

Our food system is at a pivotal moment; there is enormous potential for innovation to unlock more healthy, accessible and sustainable diets for all, but we are simultaneously facing huge global challenges.

Bayesian statistics has emerged as a powerful methodology for making decisions from data in the applied sciences. Bayesian brings a new way of thinking to statistics, in how it deals with probability, uncertainty and drawing inferences from an analysis.

The gene therapy landscape is dynamic and constantly shifting. In this article, we will review major advances in disease modification for illnesses that presently still lack effective treatments, as well as some challenges and approaches to overcome them.

Scientists have demonstrated the potential for using intratumoral microdevices (IMDs) to test various cancer drugs on the tumor before implementing systemic treatment. The approach could offer a hope in tackling hard-to-treat gliomas.